Introduction {#Sec1}
============

Although autoimmune hepatitis (AIH) with an acute presentation is difficult to diagnose based on a scoring system because of low immunoglobulin G (IgG) levels and antinuclear antibody (ANA) titers, its clinical and histological characteristics have been gradually elucidated by several reports^[@CR1]--[@CR18]^. AIH with an acute presentation includes two types: (1) the acute exacerbation phase, in which patients present with the clinical features of acute hepatitis, with histological evidence of chronic hepatitis; and (2) the acute hepatitis phase, in which patients present with histological features of acute hepatitis^[@CR11]^.

Regular nationwide surveys of AIH have been conducted since 1975 in Japan^[@CR1],[@CR2],[@CR19]--[@CR21]^. The 2015 survey reported the trends in 1682 patients who were diagnosed with AIH from 2009 to 2013^[@CR2]^. The proportion of AIH cases with acute hepatitis (11.7%) in 2015 was similar to that in 2009 (10.9%); notably, 1,056 patients were diagnosed with AIH from 2006 to 2008^[@CR1]^.

The accumulation of findings of AIH with an acute presentation^[@CR1]--[@CR18]^ and its novel diagnostic guidelines^[@CR22]^ may have affected the actual characteristics of AIH in Japan after the previous 2015 survey. The aim of this study was to elucidate the recent trends in AIH in Japan by comparing the results of the 2015 survey to a 2018 survey.

Results {#Sec2}
=======

Characteristics of patients with AIH {#Sec3}
------------------------------------

The survey population had a median age at diagnosis of 63 years, and the male-to-female ratio was 1:5.3. Compared with the 2015 survey, the 2018 survey had a significantly lower proportion of women (Table [1](#Tab1){ref-type="table"}). The distribution of age at diagnosis had a single peak in the 60 s in both surveys.Table 1Characteristics of patients upon the diagnosis of autoimmune hepatitis in 2018 and 2015.201820152015 vs. 2018VariableValueAvailable no. of patientsValueAvailable no. of patients*P*Age (years)63 (52--70)78362 (53--70)1,3860.592Female (%)84.0 (669)79688.1 (1,238)1,4050.009AST (U/L)216 (86--512)788187 (81--507)1,4070.020ALT (U/L)255 (91--628)788214 (84--543)1,4080.011ALP (U/L)430 (322--614)781424 (306--587)1,3930.304$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\gamma$$\end{document}$-GTP (U/L)158 (86--289)786146 (80--260)1,3950.041Total bilirubin (mg/dL)1.2 (0.8--4.0)7861.1 (0.7--2.8)1,3940.024Prothrombin time (INR)1.09 (1.02--1.21)719------Prothrombin time (%)84 (69--96)730------IgG (mg/dL)2090 (1,670--2,697)7692,251 (1835--2,885)1,378 \< 0.001ANA titer160 (40--640)764160 (80--640)1,362 \< 0.001ANA positivity86.2% (674)78293.8% (1,312)1,398 \< 0.001ASMA positivity37.4% (96)25742.4% (191)4500.213AMA positivity14.8% (107)72515.9% (107)6750.622LKM1 antibody positivity6.0% (13)21813.5% (56)4140.006Revised IAIHSG score15 (13--18)73115 (13--18)1,4090.412Simplified score6 (5--7)6936 (5--7)1,4100.051Hepatitis B surface antigen positivity0.6% (4)6800.3% (4)1,4020.503Hepatitis B core antibody positivity17.4% (105)60521.6% (175)8090.054Hepatitis C antibody positivity1.4% (11)7763.2% (45)1,3910.016Hepatitis C RNA positivity1.8% (3)1648.1% (24)2960.011HLA-DR4 positivity63.5% (80)12668.9% (182)2640.339HLA-DR2 positivity6.6% (8)1229.6% (24)2510.438**Histologic diagnosis**Acute hepatitis21.7% (157)72311.0% (135)1,225 \< 0.001Chronic hepatitis70.0% (506)72381.9% (1,003)1,225 \< 0.001Liver cirrhosis8.3% (60)7237.1% (87)1,2250.380**Basic histology**Interface hepatitis 0/1/231/107/55969735/270/9011,2060.014Portal inflammation 0/1/225/130/53569041/273/8671,1810.059Plasma cell infiltration 0/1/269/178/436683106/437/5841,127 \< 0.001Lobular necrosis/inflammation 0/1/2109/187/38367997/410/6171,1240.431Fibrosis 0/1/2/3/491/234/177/104/45651105/387/352/207/821,1330.005Frequency of bile duct injury22.4% (147)65623.8% (251)1,0550.549Frequency of hepatocyte rosette formation35.9% (220)61343.8% (418)9550.002Frequency of centrilobular necrosis36.2% (204)56433.0% (251)7610.250Frequency of emperipolesis28.1% (112)39814.5% (68)469 \< 0.001Frequency of fatty change18.1% (125)69117.8% (212)1,1920.917Values are expressed as median (25--75 percentile) for continuous variables or as the number of patients or as percentage (number) for categorical variables.ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; AST, aspartate aminotransferase; $\documentclass[12pt]{minimal}
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                \begin{document}$$\gamma$$\end{document}$-GTP, gamma-glutamyl transpeptidase; HLA, human leukocyte antigen; IAIHG, International AIH Study Group; IgG, immunoglobulin G; LKM, liver/kidney microsomal.

Of the 760 patients, 147 (19.3%) had a history of alcohol intake and 56 (38.1%) drank \< 20 g of ethanol per day. Of the 780 patients, 115 (14.7%) had a history of medications associated with the development of AIH; the major kinds of drugs were calcium channel blockers (13/115, 11.3%), angiotensin II receptor blockers (12/115, 10.4%), and herbal medicines (10/115, 8.7%). Only 6 of 687 patients with AIH (0.9%) had a family history of AIH. No patients developed AIH with biological and checkpoint inhibitor therapies.

Laboratory findings {#Sec4}
-------------------

The levels of aminotransferases and total bilirubin were significantly higher in the 2018 survey than in the 2015 survey (Table [1](#Tab1){ref-type="table"}). As shown in Fig. [1](#Fig1){ref-type="fig"}, compared with the patients in the 2015 survey, those in the 2018 survey had: significantly increased proportions of cases with alanine aminotransferase (ALT) levels \> 1,000 U/L and total bilirubin \> 10 mg/dL; significantly lower IgG levels, but a significantly higher proportion of cases with IgG concentration of 1--1.5 g/dL; and, of 674 cases, a significantly decreased proportion had serum ANA positivity (86.2% vs. 93.8%, *p* \< 0.001) and an ANA titer of 1:80, but a significantly increased proportion had an ANA titer ≤ 1:40. Most patients positive for liver-kidney microsomal (LKM) antibody were also positive for ANA or anti-smooth muscle antibody. Only one patient (0.5%) in the 2018 survey and two patients (0.5%) in the 2015 survey were positive for LKM antibody alone; they were classified as having type 2 AIH. On the other hand, 692 patients (88.5%) in the 2018 survey and 1,357 (97.1%) in the 2015 survey were classified as having type 1 AIH. No patients had other autoantibodies, such as antibodies against soluble liver antigen/liver pancreas or antineutrophil cytoplasmic antibody.Figure 1Comparison between the 2015 survey (white bar) and the 2018 survey (black bar) in the distribution of serum (**a**) alanine aminotransferase (*ALT*) levels, (**b**) total bilirubin levels, (**c**) immunoglobulin G (*IgG*) levels, and (**d**) antinuclear antibody (*ANA*) titers at diagnosis in patients with autoimmune hepatitis.

Liver histological findings {#Sec5}
---------------------------

Of the 723 patients whose data on histological assessment of the liver were available, 70.0% were diagnosed with chronic hepatitis and 21.7% were diagnosed with acute hepatitis; the latter was significantly more frequent in the 2018 survey than in the 2015 survey (21.7% vs. 11.0%, *p* \< 0.001) (Table [1](#Tab1){ref-type="table"}). The frequency of acute hepatitis was also significantly increased, from 13.8% in 2015 to 23.7% in 2018, in the 28 facilities that completed both surveys (Supplemental Table [2](#MOESM1){ref-type="media"}). With regard to basic histological characteristics of the cases in the 2018 survey, compared with those in the 2015 survey, interface hepatitis and plasma cell infiltration were significantly more pronounced; the number of cases that had no fibrosis was higher, despite the similar frequency of centrilobular necrosis; emperipolesis was significantly increased; and hepatocyte rosette formation was decreased.Table 2Diagnosis and severity of autoimmune hepatitis.201820152015 vs. 2018Frequency/valueAvailable noFrequency/valueAvailable no*P***Diagnosis***Japanese guide 2013*Typical80.4% (562)699--Atypical19.6% (137)699--*Revised score*--Definite48.8% (385)78948.0% (677)1,4090.770Probable47.8% (377)78948.3% (680)1,4090.864Other3.4% (27)7893.7% (52)1,4090.838*Simplified score*Definite45.7% (349)76338.2% (538)1,410 \< 0.001Probable31.1% (237)76333.6% (476)1,4100.219Other23.2% (177)76328.1% (396)1,4100.016**Severity**Mild38.5% (297)771Moderate43.6% (336)771Severe17.9% (138)771*(Clinical signs)*Hepatic encephalopathy1.9% (14)753Reduction or disappearance of hepatic dullness2.1% (15)710*(Clinical laboratory tests)*AST/ALT of more than 200 U/L60.9% (480)788Bilirubin of \> 5 mg/dL21.6% (170)786Prothrombin time \< 60%16.2% (119)734*(Imaging tests)*Hepatic atrophy4.2% (31)745Heterogeneous liver parenchyma11.1% (82)740Values are given as the percentage (number).ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Diagnosis and severity of AIH {#Sec6}
-----------------------------

Most patients were diagnosed within 6 months from estimated onset in both surveys (2018: 79.0%, 2015: 77.2%; *p* = 0.361). In the 2018 survey, 80.4% had typical cases, based on the Japanese guidelines; whereas definite cases were seen in 48.8%, based on the revised score, and 45.7%, based on the simplified score (Table [2](#Tab2){ref-type="table"}). The severity of AIH was mild in 38.5%, moderate in 43.6%, and severe in 17.9%. Of the items evaluating severity, clinical laboratory tests had relatively high frequencies of abnormalities, whereas clinical signs had low frequencies of abnormalities.

Comorbidity {#Sec7}
-----------

Other autoimmune diseases were present in 194 of 787 patients (24.7%) with AIH, and this frequency was similar to that in the 2015 survey (24.9%) (Table [3](#Tab3){ref-type="table"}). In the 194 AIH patients with other autoimmune diseases, the most frequent was chronic thyroiditis (8.3%), followed by Sjögren's syndrome (6.6%), rheumatoid arthritis (2.7%), and primary biliary cholangitis (2.4%). The order by frequency was exactly the same as in the previous 2015 survey. However, the frequency of malignancy increased significantly from 6.4% in 2015 to 10.3% in the present survey (*p* = 0.001). In patients with malignancy, the most frequent complication was gastric cancer (1.8%), followed by colon cancer (1.7%) and breast cancer (1.7%).Table 3Comorbidity and Treatment in patients with autoimmune hepatitis in 2018 and 2015.No. of patients2015 versus 201820182015*P***Comorbidity***Autoimmune disorder*24.7% (194/787)24.9% (347/1,395)0.948Chronic thyroiditis8.3% (65)8.0% (111)Sjögren's syndrome6.6% (52)6.6% (92)Rheumatoid arthritis2.7% (21)3.7% (51)Primary biliary cholangitis2.4% (19)2.8% (39)Systemic sclerosis1.8% (14)0.8% (11)Graves' disease1.8% (14)1.1% (16)Systemic lupus erythematosus1.5% (12)2.4% (34)Idiopathic thrombocytopenic purpura0.6% (5)0.7% (10)Raynaud's phenomenon0.5% (4)0.9% (12)Dermatomyositis/polymyositis0.5% (4)0.4% (6)Others2.3% (18)1.9% (26)*Malignancy*10.3% (81/784)6.4% (88/1,383)0.001Gastric cancer1.8% (14)0.8% (11)Colon cancer1.7% (13)0.7% (9)Breast cancer1.7% (13)1.0% (14)Uterine or ovarian cancer1.0% (8)0.4% (6)Lung cancer0.9% (7)0.5% (7)Hepatocellular carcinoma0.6% (5)0.8% (11)Others2.9% (23)2.2% (31)**Treatment**Prednisolone85.5% (665/778)80.9% (1,129/1,396)0.008 Prednisolone alone31.8% (204/642)30.0% (331/1,103)0.473 Initial dose of prednisolone (mg/day)40 (30--40)30 (30--40) \< 0.001 Maintenance dose of prednisolone (mg/day)5 (5--7.5)5(5--7.5)0.281 Steroid pulse therapy, n (%)19.1% (122/640)13.3% (138/1,036)0.002 Prednisolone + ursodeoxycholic acid63.0% (409/649)64.7% (714/1,103)0.503 Efficacy of prednisolone97.8% (575/588)97.6% (1,008/1,033)0.923 Relapse during prednisolone therapy23.2% (141/609)24.7% (247/1,000)0.520Azathioprine12.3% (80/648)9.4% (128/1,362)0.051Ursodeoxycholic acid alone10.9% (81/744)15.6% (213/1,362)0.003Without treatment2.4% (18/744)2.0% (27/1,363)0.612Biochemical remission after 6 months of therapy58.4% (330/565)\--Values are given as the percentage (number) for categorical variables or as median (25^th^--75th percentile) for continuous variables.

Treatment {#Sec8}
---------

There were 665 of 778 patients (85.5%) who were treated with prednisolone; of these, 409 (63.0%) were treated with a combination of prednisolone and ursodeoxycholic acid (UDCA), and 204 (31.8%) were treated with prednisolone alone (Table [3](#Tab3){ref-type="table"}). Furthermore, 122 patients (19.1%) were treated with steroid pulse therapy. Compared with the 2015 survey, the 2018 survey had significantly higher frequencies of prednisolone treatment (85.5% vs. 80.9%; *p* = 0.008), including pulse (19.1% vs. 13.3%; *p* = 0.002). The initial dose of prednisolone was higher in the 2018 survey than in the 2015 survey (40 mg vs. 30 mg, *p* \< 0.001). Initial dosages of 31--50 mg daily were significantly increased, while those of ≤ 30 mg daily were significantly decreased (Fig. [2](#Fig2){ref-type="fig"}). The 2018 and 2015 surveys had similar efficacy rates of prednisolone (97.8% vs. 97.6%, respectively; *p* = 0.923) and rates of relapse during prednisolone treatment (23.2% vs. 24.7%, respectively; *p* = 0.520). Eighty patients (12.3%) were treated with azathioprine. Of the 113 patients who did not receive prednisolone treatment, 81 (71.7%) were treated with UDCA alone and 18 (15.9%) were followed up without treatment. The rate of biochemical remission after 6 months of therapy was 58.4% in the 2018 survey. The rate was significantly higher in patients receiving prednisolone alone than in those receiving UDCA alone (68.4% vs. 32.7%, respectively; *p* \< 0.001).Figure 2Comparison between the 2015 survey (white bar) and the 2018 survey (black bar) in the distribution of the initial dosage of prednisolone.

Outcome {#Sec9}
-------

During the 3-year survey period, 9 patients (1.1%) died of liver-related causes and 1 patient (0.1%) received a liver transplant. The male-to-female ratio was 1:2.3, and the mean age at diagnosis was 63.2 years in these 10 patients.

Discussion {#Sec10}
==========

The prevalence of acute AIH has not been reported in countries other than Japan. The Japanese nationwide survey in 2009 was the first to report that 95 of 871 (10.9%) patients with AIH had acute hepatitis^[@CR1]^; this frequency remained steady at 11.7% in the 2015 survey^[@CR2]^, but it increased significantly to 21.7% in the 2018 survey. To the best of our knowledge, this evidence of an increasing trend of acute AIH was the first to be reported worldwide.

In the present survey, the high prevalence of acute AIH may have affected the AIH characteristics found. The high number of cases that showed no fibrosis on histology was likely directly reflective of the high prevalence of AIH with acute hepatitis. On the other hand, the increased incidence of acute hepatitis was reflected more in the laboratory findings than in the histological findings. In addition to the elevated levels of aspartate aminotransferase (AST), ALT, and total bilirubin, a low IgG level and a low ANA titer were found as characteristics of acute AIH in the previous survey^[@CR14],[@CR16]^. The changes in prednisolone treatment, such as the initial dose or frequency of pulse therapy, may have reflected the increasing incidence of acute hepatitis. The reason could be that, in the 2015 survey of AIH patients, the initial dosage of prednisolone was higher and pulse therapy was more frequent in patients with acute hepatitis than in those with chronic hepatitis^[@CR2]^.

The precise reason for the increasing incidence of acute AIH has not been elucidated, although some factors can be considered. First, the Japanese diagnosis and treatment guidelines that were proposed in 2014^[@CR22]^ may have led to increased diagnosis of AIH, including acute presentation. In fact, in the present survey, the frequency of typical cases, as defined by the Japanese guidelines, was higher than that of definite cases, as defined by the revised or simplified criteria of the IAIHG. Second, in 2015 in Japan, AIH was designated an intractable disease that can be treated with free drugs. However, fulminant hepatitis was excluded from this list of designated intractable diseases. This system change may have increased the diagnosis of acute liver failure as AIH. Third, the biases of the specific hospitals and clinics that completed the present survey may have affected the results. However, the present results showed a trend of increasing incidence of AIH with acute hepatitis, regardless of the facilities.

In the present survey, there were some changes that cannot be attributed to the increasing incidence of acute hepatitis. The significant increase in the incidence of malignancy can reflect the increasing trend in the general population^[@CR23]^. Moreover, the present study included relatively fewer women, although the male-to-female ratio of 1:5.3 in the present study was the same as the 1:4.3 ratio in a recent epidemiological study in Japan^[@CR24]^.

Although the strengths of the present study were the large sample size and the new trend in AIH, there are several limitations. First, the number of subjects in the 2018 survey was lower than in the 2015 survey, because it was more detailed and took more time. However, the 2018 survey provided new information, such as severity and treatment responses. Furthermore, the trend of acute hepatitis was confirmed in the facilities that completed both the 2015 and 2018 surveys. The second limitation of the present study was the definition of acute hepatitis, which was based on histological findings by each pathologist. Therefore, acute hepatitis cases in the present survey may have included acute exacerbation of chronic hepatitis, because the histological definition of acute hepatitis has not been elucidated. On the other hand, previous nationwide surveys in Japan have reported the prevalence of acute hepatitis using the same definition; thus, use of the same definition of acute hepatitis would allow a comparison of its prevalence. Although the two phenotypes of acute presentation in the Japanese guidelines are not largely different from the concepts in the European Association for the Study of the Liver clinical practice guidelines^[@CR24]^, validation of the definition in other cohorts, not only in Japan but also in other countries, is needed. Third, ANA is measured mostly by indirect immunofluorescence (IF) methods using human epithelial (HEp-2) cells in Japan. The high correlation between measurement using frozen liver tissue and that using HEp-2 cells is confirmed; therefore, indirect IF methods using HEp-2 cells are recommended in Japan. Fourth, patients without liver histology were included if they satisfied the revised or simplified criteria. Therefore, patients with drug-induced liver injury or drug-induced AIH-like injury may have been included in the present study. Fifth, the prognosis of patients having AIH with acute hepatitis cannot be determined from this survey, because the subjects were newly diagnosed from 2014 to 2017. Development of internationally uniform diagnostic methods and future surveys of acute AIH will address these limitations.

In conclusion, AIH with acute hepatitis in Japan was shown to have an increasing incidence and changing characteristics. The present nationwide survey suggests the need for new strategies for the accurate diagnosis and elucidation of the mechanisms in acute AIH.

Methods {#Sec11}
=======

Participants {#Sec12}
------------

A total of 138 hospitals (not including pediatric centers) that had hepatology specialists were asked to complete questionnaires about patients who were newly diagnosed with AIH from 2014 to 2017. Of the 138 hospitals, 54 returned the questionnaires from 923 AIH patients. After excluding patients who had been diagnosed with AIH before 2014 and did not satisfy the revised^[@CR26]^ or simplified criteria^[@CR27]^ of AIH, a total of 796 patients were enrolled in this study. Of the 1687 patients in the previous nationwide survey in 2015, 1,410 who satisfied the revised or simplified criteria of AIH were also included in this study. The Ethics Committee of Fukushima Medical University (Fukushima Medical University protocol number: 29182) approved this study protocol, which waived the need for written, informed consent because this was an observational study. Instead of written, informed consent, information about this study was released, and participants were given the right to opt out. This survey was conducted in accordance with the Declaration of Helsinki.

Questionnaire {#Sec13}
=============

The questionnaire included items about age at diagnosis; sex; medical and family history; alcohol and history of medication associated with the development of AIH; laboratory and liver histological findings; diagnosis based on the revised and simplified diagnostic scores, as proposed by the International AIH Study Group (IAIHG)^[@CR26],[@CR27]^; diagnosis and severity grading based on the Japanese guidelines^[@CR22]^; clinical symptoms; imaging findings; presence of other autoimmune or malignant diseases; treatments; and outcomes. The autoantibodies were tested by the methods used in each hospital, such as indirect IF or enzyme-linked immunosorbent assays. Severity grading was classified into mild, moderate, and severe based on a combination of clinical signs (hepatic encephalopathy, reduction or disappearance of hepatic dullness), clinical laboratory tests (AST/ALT \> 200 U/L, bilirubin \> 5 mg/dL, prothrombin time \< 60%), and imaging tests (hepatic atrophy, heterogeneous liver parenchyma pattern) (Supplemental Table [1](#MOESM1){ref-type="media"}). Steroid pulse therapy was defined as high-dose i.v. corticosteroids (\> 125 mg methylprednisolone/body/day). Similar to a previous survey^[@CR5]^, in addition to liver histological diagnoses such as acute hepatitis, chronic hepatitis, and cirrhosis, the present survey graded basic histology as interface hepatitis; portal inflammation; plasma cell infiltration; lobular necrosis or inflammation (0, absent; 1, mild; or 2, moderate to severe); fibrosis (0, absent; 1, mild; 2, moderate; 3, severe; or 4, cirrhosis); bile duct injury; hepatocyte rosette formation; centrilobular necrosis; emperipolesis; and fatty change (0, absent; 1, present). Acute hepatitis was defined based on histological diagnosis by the pathologists in each hospital. Biochemical remission was defined as normalization of transaminase (\< 30 U/L) and IgG (\< 1,700 mg/dL) levels.

Statistical analysis {#Sec14}
--------------------

The data are presented as medians for continuous variables and as percentages for categorical variables. Differences between the two groups (2018 survey and 2015 survey) were analyzed using the Mann--Whitney *U*-test for continuous variables and the χ^2^ test or Fisher's exact test for categorical variables. To account for possible bias among the participating hospitals and clinics in the comparison of histological diagnoses, only the 28 facilities that completed both the 2015 and 2018 surveys were analyzed. Statistical analyses were performed with SPSS ver. 25.0 (SPSS Inc., Chicago, IL). A *p* value of \< 0.05 was considered significant.
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